This study was undertaken to identify the role of scavenger receptors in the catabolism of lipopolysaccharide (LPS) and lipoteichoic acid (LTA). LPS is mainly cleared from the blood by the liver. The Kupffer cells are primarily responsible for this clearance. Although several binding sites have been described for LPS and LTA, only CD14 is involved in LPS signalling. Scavenger receptor type A (SR-A) is expressed in the liver on endothelial cells and Kupffer cells, and macrosialin (class D scavenger receptor) is expressed on Kupffer cells. Fucoidin and poly-I are both good inhibitors of scavenger receptors. Fucoidin significantly reduced the serum clearance of [ 125 I]-LPS and decreased liver uptake of [ 125 I]-LPS by ~40%. Poly-I inhibited the binding of [ 125 I]-LPS to isolated Kupffer and endothelial cells by 75%, while poly-A, a polyanionic substrate that does not block scavenger receptors, had no effect. LPS significantly inhibited the binding of acetylated LDL and oxidized LDL (two well-described scavenger receptor ligands) to isolated Kupffer and liver endothelial cells. OxLDL and acLDL did not affect the binding of LPS to these cells. We conclude that on both endothelial cells and Kupffer cells, LPS mainly binds to scavenger receptors, but SR-A and macrosialin contribute to a limited extent to the binding of LPS. Injection of LTA into C57Bl6 mice resulted in a maximal liver uptake of 20% of the injected dose. In the liver, 50% was bound by the Kupffer cells, 20% by parenchymal cells and 30% by liver endothelial cells. The contribution of SR-A to the plasma clearance of LTA was limited. A main component in the catabolism of LTA is the interaction of LTA with plasma lipoproteins, which limit the uptake of LTA by tissues and extend the plasma half-life of LTA.
INTRODUCTION
During the past decades, the incidence of sepsis and septic shock due to bacterial infections has increased. In the US, septic shock causes up to 250,000 deaths annually. Bacteremia evokes an excessive response of the immune system, resulting in hypotension, tachycardia, disseminated intravascular coagulation (DIC), multiple organ failure (MOF), and death. Many studies have focused on the role of Gram-negative bacteria in the development of sepsis and septic shock; the cell wall component lipopolysaccharide (LPS) has been identified as the main component of Gram-negative bacteria that is responsible for the induction of sepsis and septic shock by these bacteria. On the other hand, infections with Gram-positive bacteria are now estimated to cause over 50% of all cases of septicemia. 1 In particular, infections with Staphylococcus aureus and Staphylococcus epidermidis are responsible for about 50% of the cases of Gram-positive sepsis. The immunogenic compounds of the Gram-positive bacteria comprise lipoteichoic acid (LTA), peptidoglycans (PG), capsule polysaccharides, teichoic acid, proteins, and toxins that may all contribute to the host response.
In the present paper, we focus on the role of liver receptors in the clearance of LPS and LTA. Several receptors have been identified that interact with LPS, but the receptors involved in the clearance of LPS and particularly LTA have not been described in great detail. Interestingly, CD14 was originally found to bind LPS and to be involved in cellular activation. However, CD14 is also involved in the binding of LTA and the subsequent activation. 2 Other receptors have also been implicated in the binding of LPS and/or LTA -in particular, the scavenger receptors. [3] [4] [5] [6] [7] In the last years, several classes of scavenger receptors have been identified and their binding profile varies from binding unmodified lipoproteins (class B, SR-BI and CD36) to modified lipoproteins (class A, SR-A and MARCO and class D, CD68). In addition to lipoproteins, these scavenger receptors may recognize the negative charge of LPS or LTA and, therefore, interact with these bacterial products. In general, it is believed that scavenger receptor binding of these bacterial products does not lead to cellular activation. In addition to the scavenger receptors, several other receptors may interact with LPS: the CD11/CD18 complex is able to bind LPS, which may lead to NF-κB stimulation. 8 A heptose-specific receptor for LPS is located on parenchymal liver cells. 9 A metabolic response upon binding of LPS to this receptor has not been reported.
In our studies, we have focused on the role of scavenger receptors on Kupffer and endothelial liver cells in the clearance and binding of LPS and LTA.
MATERIALS AND METHODS
Chemicals 125 I, sodium salt, was obtained from Amersham, Buckinghamshire, UK; collagenase type IV, bovine serum albumin (BSA) fraction V, fucoidin, poly-inosinic acid (poly-I), and poly-adenylic acid (poly-A), and LTA from Staphylococcus aureus (lot 17H4114), isolated by phenol extraction, were purchased from Sigma Chemical Co. (St Louis, MO, USA). Salmonella minnesota Re595 LPS was from List Biological Laboratories Ltd. (Campbell, CA, USA).
Isolation and modification of low-density lipoproteins
LDL (d = 1.019-1.063 g/ml) was isolated by density gradient ultracentrifugation as described. 10 Immediately after isolation, 40 µM BHT was added to the LDL, except for the LDL used for oxidative modification. Acetylation of LDL and Cu 2+ oxidation of LDL were performed as described previously. 3 
Labelling of lipopolysaccharide
LPS and LTA labelling was with 125 I according to the method of Ulevitch. 10 The labelled preparations were checked by agarose gel electrophoresis, fast performance liquid chromatography (FPLC) analysis and activation of RAW cells (NO and TNF production).
Serum decay, liver uptake, and organ distribution
Rats (220-350 g) and mice were anaesthetized and abdomens were opened. 11 [ 125 I]-LPS or [ 125 I]-LTA were injected via the vena cava inferior. At the indicated times, blood samples of 50-300 µl were withdrawn and serum samples were counted for radioactivity, while at the indicated times, liver lobules were tied off and removed. The liver lobules were weighed and radioactivity was determined. Radioactivity was corrected for radioactivity in serum determined to be present at the time of sampling.
Liver cell distribution
Perfusion of the liver using Hanks' buffer was started at 8°C or 37°C. The liver was subsequently perfused with collagenase (0.05% w/v), and parenchymal cells were separated from non-parenchymal cells using differential centrifugation. The endothelial cells and Kupffer cells were separated using centrifugal elutriation as described previously. 11 
Binding studies
Isolated endothelial and Kupffer liver cells were incubated with [ 125 I]-LPS, in the presence or absence of a competitor at 4°C for 2 h. After the incubation, the cells were washed twice with Tris-buffered saline containing 0.2% BSA, pH 7.4, and once with buffer without BSA. Cells were counted for radioactivity and protein was determined subsequently according to the method of Lowry with BSA as the standard.
Statistical analysis
Statistical significance was determined using a two-way ANOVA or a two-tailed Student's t-test.
RESULTS AND DISCUSSION
In vivo, the serum decay of [ 125 I]-LPS in rats that received a pre-injection of fucoidin was decreased in comparison to the serum decay of [ 125 I]-LPS in control rats (Fig. 1A) . Injection of [ 125 I]-LPS lead to a biphasic serum decay, and ~90% of the LPS was cleared in the first phase (t 1/2 <2 min). Pre-injection of fucoidin reduced the initial clearance of LPS to 65% of the injected dose in the first 5 min. Rat livers maximally take up 82.0 ± 10.0% of the injected dose ( Fig. 1B) , while pre-injection of fucoidin reduced the liver uptake to 57.6 ± 2.5% of the injected dose which is a 34% reduction. In control rats, Kupffer cells showed a specific binding of 1179 ± 233% of initial dose x10 3 /mg cell protein, while fucoidin decreased the binding of [ 125 I]-LPS to Kupffer cells by 72%. The specific binding of [ 125 I]-LPS to endothelial cells in control rats was reduced by fucoidin from 292 ± 52% of initial dose x10 3 /mg cell protein to 84 ± 37% of initial dose x10 3 /mg cell protein.
No effect of fucoidin on the specific binding of [ 125 I]-LPS to the parenchymal cells could be observed ( Table  1 ). The effect of fucoidin, a scavenger receptor blocker, indicates that scavenger receptors play a role in the catabolism of LPS. The class A (SR-A and MARCO) and class D (CD68 or macrosialin) scavenger receptors are the main scavenger receptors that are inhibited in their ligand binding by fucoidin. It should be added that MARCO is not highly expressed within the liver. The main ligands for SR-A and CD68 are acLDL and oxLDL, respectively, and these ligands were subsequently used to inhibit the binding of LPS to isolated Kupffer and endothelial liver cells. Unlabelled LPS inhibited the binding of [ 125 I]-LPS to endothelial and Kupffer cells by 85 ± 2% and 86 ± 1% with a K i of ~10 µg/ml, respectively, indicating that specific binding sites were involved in the interaction of LPS with those cells ( Table 2 ). The general scavenger receptor ligand, poly-I, inhibited the binding of [ 125 I]-LPS to endothelial and Kupffer cells by 78 ± 3%, and 75 ± 10% with a K i of 2 µg/ml. Poly-A had no effect on the binding of LPS to both cell types. The modified lipoproteins OxLDL and acLDL were not able to inhibit binding of [ 125 I]-LPS to endothelial or Kupffer cells. LPS, however, was able to inhibit the binding of [ 125 I]-acLDL to endothelial cells and Kupffer cells by 50% and the binding of [ 125 I]-oxLDL to these cells by 60%. To estimate the contribution of CD14 to the binding of LPS by Kupffer cells, Kupffer cell CD14 was removed by phospholipase C treatment. Phospholipase C treatment had no significant effect on the total binding of [ 125 I]-LPS. The results from these in vitro binding studies indicate that the SR-A, CD68 and CD14 are not primarily involved in the binding of LPS. A poly-I-sensitive site is, however, primarily responsible for the binding of LPS, but a scavenger receptor specifically responsible for the binding of LPS has not yet been identified by us in the large and rapidly growing family of these receptors .
Next we focused on the in vivo fate of [ 125 I]-LTA in mice. Upon injection, a plasma clearance is observed which is much slower than the plasma clearance of LPS in rats. The plasma half-life exceeds 30 min (Fig. 2) . As a consequence, the liver uptake of LTA is much lower than that of LPS and, after 30 min, 18% of the injected dose is recovered in the liver. Liver cell distribution experiments indicated that 46 ± 5% of the amount of LTA in the liver was taken up by the Kupffer cells, 21 ± 6% by the liver parenchymal cells and 33 ± 5% by the liver endothelial cells. The other tissues that contribute to the plasma clearance of LTA were primarily the kidneys, skin and bone, but their contribution did not exceed 5% of the injected dose. The main reason for the lower interaction of LTA with the liver was found to be the interaction of LTA with plasma lipoproteins. The analysis of the plasma lipoproteins in mice indicated that LTA interacted in C57Bl6 mice primarily with HDL, which is the main lipoprotein in their serum. In transgenic mice, like apoE-deficient mice, LTA interacts primarily with VLDL, which is the main plasma lipoprotein in these mice (Fig. 3) . The conclusions on the catabolism of LTA are that the catabolism is mainly the result of a competition between the liver and the plasma lipoproteins. A higher concentration of lipoproteins, as observed in apoE-deficient mice, results in a decreased liver uptake of LTA. LTA seems not to have a preference for any type of lipoproteins, and preliminary results with isolated lipoproteins indicate that LTA is incorporated in HDL, LDL and VLDL at the same rate.
The role of scavenger receptor type-A in the catabolism of LTA was determined using SR-A deficient mice, which were constructed by the group of Kodama. 12 In these mice, we observed a reduced liver interaction of LTA indicating a role for SR-A in the uptake of LTA by the liver. In addition, we also determined in SR-A-deficient mice the clearance and liver uptake of LPS. We found that the liver uptake of LPS was similar in both mice, indicating that, under physiological conditions, SR-A does not quantitatively contribute to the plasma clearance of LPS.
Removal of the Kupffer cells by pre-injection of animals with dichloromethylene-bisphosphonate liposomes results in a larger decrease in SR-A knockout mice than in wildtype mice indicating that, under these conditions, SR-A may play a role in the liver uptake of LPS. These results underline the aforementioned conclusions that an as yet unidentified scavenger receptor contributes largely to the liver uptake of LTA and LPS. 
